Concepedia

Publication | Open Access

Real-world safety and effectiveness of iGlarLixi in people with type 2 diabetes who fast during Ramadan: The SoliRam observational study

DOIFull Paper Access

14

Citations

7

References

2023

Year

Mohamed Hassanein, Rachid Malek, Inass Shaltout, Rakesh Sahay, Mehmet Akif Büyükbeşe, Khier Djaballah, Valérie Pilorget, Mathieu Coudert, Saud Al Sifri
Diabetes & Metabolic Syndrome Clinical Research & Reviews

Abstract

iGlarLixi is an effective and well-tolerated therapy for people with T2D, including those who intend to fast during Ramadan, and is associated with a low risk of hypoglycemia; benefits were observed both during and after Ramadan.

References

YearCitations

Page 1